Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gain Therapeutics (GANX) Shares Outstanding (Weighted Average) (2020 - 2025)

Gain Therapeutics (GANX) has 6 years of Shares Outstanding (Weighted Average) data on record, last reported at $31.4 million in Q3 2025.

  • For Q3 2025, Shares Outstanding (Weighted Average) rose 18.17% year-over-year to $31.4 million; the TTM value through Sep 2025 reached $31.4 million, up 18.17%, while the annual FY2024 figure was $22.9 million, 75.86% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $31.4 million in Q3 2025 per GANX's latest filing, up from $30.3 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $31.4 million in Q3 2025 and bottomed at $4.9 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $16.4 million, with a median of $12.2 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Weighted Average): skyrocketed 499.29% in 2021, then grew 0.06% in 2022.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $10.2 million in 2021, then rose by 16.9% to $11.9 million in 2022, then increased by 9.49% to $13.0 million in 2023, then skyrocketed by 75.86% to $22.9 million in 2024, then soared by 37.02% to $31.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Weighted Average) were $31.4 million in Q3 2025, $30.3 million in Q2 2025, and $28.7 million in Q1 2025.